Yes, both chemotherapy and immunotherapy are widely available on the NHS for different stages of bladder cancer. For early stage tumours, liquid medications are put directly into the bladder. For advanced or metastatic cancer, systemic treatments like intravenous chemotherapy or the latest breakthrough immunotherapy combinations are offered to help shrink tumours and extend life.
What We will cover in this Article
- Types of intravesical chemotherapy for superficial tumours
- The use of BCG immunotherapy in the NHS for high risk cases
- Standard intravenous chemotherapy for muscle invasive cancer
- The breakthrough combination of enfortumab vedotin and pembrolizumab
- How the NHS determines eligibility for these treatments
- Managing the different side effects of these therapies
Chemotherapy and immunotherapy on the NHS
The NHS provides a comprehensive range of drug treatments for bladder cancer based on the specific stage and risk level of the disease. For non muscle invasive bladder cancer, which is cancer that has not reached the bladder muscle, doctors use intravesical therapy. This involves inserting a liquid drug into the bladder through a small tube. These drugs either kill cancer cells directly (chemotherapy) or stimulate the body’s own immune system to destroy them (immunotherapy).
For patients with more advanced disease, such as muscle invasive or metastatic bladder cancer, the NHS offers systemic treatments. These drugs travel through the bloodstream to reach cancer cells throughout the body. These are usually given as an infusion in a hospital day unit. Recent updates to NHS funding have introduced highly effective new drug combinations that have significantly improved survival rates for those with advanced disease.
Key treatment pathways include:
- Intravesical chemotherapy (Mitomycin C or Epirubicin) for low to intermediate risk cases
- Intravesical immunotherapy (BCG) for high risk superficial tumours
- Neoadjuvant chemotherapy given before surgery to shrink tumours
- First line combination immunotherapy for cancer that has spread
Intravesical treatments for early stage cancer
Intravesical therapy is the primary way the NHS manages superficial bladder tumours after they have been surgically removed. By putting the drug directly into the bladder, doctors can use a high concentration of the medicine while avoiding the side effects usually associated with systemic cancer drugs. This is because very little of the drug enters the bloodstream.
| Treatment Type | Primary Medication | How It Works |
| Intravesical Chemotherapy | Mitomycin C or Epirubicin | Kills cancer cells that may remain after surgery. |
| Intravesical Immunotherapy | BCG (Bacillus Calmette Guérin) | Stimulates the immune system to attack the bladder lining. |
The BCG vaccine is particularly effective for high risk superficial bladder cancer. It is the same vaccine used for tuberculosis, but when placed in the bladder, it triggers a strong immune response. Patients typically receive an initial six week course followed by maintenance sessions that can continue for up to three years.
Breakthrough treatments for advanced cancer
In 2025, the NHS approved a major breakthrough for advanced bladder cancer that has spread or cannot be removed by surgery. This treatment combines two drugs: enfortumab vedotin and pembrolizumab. This combination has been shown to nearly double survival times compared to traditional chemotherapy. Enfortumab vedotin targets cancer cells and delivers a chemotherapy payload, while pembrolizumab helps the immune system recognize and fight the disease.
‘This combination treatment represents one of the most significant advances in bladder cancer care in decades,’ stated a leading NHS oncology specialist during the 2025 clinical trials. This therapy is now available through the Cancer Drugs Fund for patients who meet specific eligibility criteria. It has replaced standard platinum based chemotherapy as the first choice for many people with metastatic disease.
Other systemic options on the NHS:
- Cisplatin and Gemcitabine (standard systemic chemotherapy)
- Avelumab (used as maintenance therapy after chemotherapy)
- Nivolumab or Atezolizumab (alternative immunotherapies for specific cases)
Causes and triggers for drug therapy
The need for chemotherapy or immunotherapy is triggered when a tumour is identified as having a high risk of coming back or spreading. The underlying causes of these tumours, such as long term tobacco use or industrial chemical exposure, result in cellular damage that requires more than just surgery to manage. Drug therapy acts as an extra layer of protection to clean up microscopic cells that a surgeon cannot see.
Clinical triggers for starting drug therapy include:
- Biopsy results showing high grade or aggressive cells
- The presence of multiple tumours at the time of diagnosis
- Cancer cells found in the muscle wall during a TURBT procedure
- Recurrence of tumours after previous surgical removals
Side effects and safety
While intravesical treatments are generally well tolerated, they can cause local irritation. Side effects often feel like a bladder infection, including a frequent need to pee or a stinging sensation. Systemic treatments given via a drip carry a different set of risks, such as fatigue, nausea, or a higher risk of infection. Your NHS clinical nurse specialist will provide a 24 hour contact number in case you experience any severe symptoms during your treatment.
Important safety notes:
- Wash your hands and genitals thoroughly after passing urine for six hours after treatment
- Use effective contraception as these drugs can affect fertility and unborn babies
- Avoid caffeine and alcohol on treatment days to reduce bladder irritation
- Report any high temperature or signs of an allergic reaction immediately
My final conclusion
The NHS offers a wide range of highly effective chemotherapy and immunotherapy options for bladder cancer patients. From intravesical washes for early disease to the latest life extending combinations for advanced cases, the UK continues to update its protocols to include the best available evidence based care. Your oncology team will work with you to choose the safest and most effective path for your specific diagnosis.
If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Will I lose my hair with bladder chemotherapy?
Intravesical chemotherapy put directly into the bladder does not cause hair loss, though systemic chemotherapy given by a drip might.
Is BCG treatment available at every hospital?
Most large NHS trusts offer BCG, but some smaller hospitals might refer you to a specialist urology centre for this treatment.
Can I drive after having bladder immunotherapy?
Most people feel well enough to drive, but you should check with your doctor if you feel tired or have significant bladder discomfort.
How long does a chemotherapy infusion take?
Systemic infusions usually take a few hours in a day unit, while intravesical treatments take about one to two hours including the waiting time.
What is the Cancer Drugs Fund?
This is an NHS system that provides fast access to promising new cancer medicines while more evidence is collected on their long term benefits.
Are these treatments free on the NHS?
Yes, all cancer treatments, including the latest immunotherapies, are provided free of charge to eligible patients through the NHS.
What happens if BCG is not available?
Sometimes there are global shortages of BCG, and in these cases, the NHS may use alternative chemotherapy washes like Mitomycin or offer more frequent check ups.
Authority Snapshot
This article was written by Dr. Rebecca Fernandez, a UK trained physician with an MBBS and extensive experience in internal medicine, general surgery, and emergency care. Having managed critically ill patients and worked in acute trauma settings, Dr. Fernandez provides information that follows the latest NHS and NICE clinical standards. Her background in patient assessment and digital health solutions helps make complex medical pathways accessible to the public.
